RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
VIA Pharmaceuticals Stock

VIA Pharmaceuticals ROA 2024

VIA Pharmaceuticals ROA

0

Ticker

VIAP

ISIN

US92554T1034

In 2024, VIA Pharmaceuticals's return on assets (ROA) was 0, a 0% increase from the 0 ROA in the previous year.

VIA Pharmaceuticals Aktienanalyse

What does VIA Pharmaceuticals do?

VIA Pharmaceuticals is a biopharmaceutical company specializing in the development of drugs for the treatment of cardiovascular diseases. The company was founded in 1999 in San Francisco. The vision of VIA Pharmaceuticals from the beginning was to develop more innovative therapies for the treatment of cardiovascular diseases that are more effective and have fewer side effects compared to existing treatment options. The company focuses on the discovery and exploration of new active substances and technologies that target the causes of cardiovascular diseases. VIA Pharmaceuticals' business model is based on collaboration with other biopharmaceutical companies and research institutes. For example, the company collaborates with the Cleveland Clinic and the University of California to advance the development of new drugs. Collaboration with investors and financial institutions also plays an important role in VIA Pharmaceuticals' business model. The various divisions of VIA Pharmaceuticals specialize in the treatment of cardiovascular diseases. In particular, drugs for the treatment of atherosclerosis, one of the main causes of cardiovascular diseases, are being developed. VIA Pharmaceuticals' research focuses on reducing inflammation and blood lipids. The products of VIA Pharmaceuticals are currently still in clinical development. One of the most promising products of the company is VIA-2291, a drug for the treatment of atherosclerosis. The drug specifically targets inflammation in blood vessels, reducing the risk of plaques and thrombosis. VIA-2291 has already shown promising results in clinical trials and is currently in phase 3 of clinical development. Other products of VIA Pharmaceuticals are in various stages of clinical development. Overall, VIA Pharmaceuticals is an innovative biopharmaceutical company specializing in the development of drugs for the treatment of cardiovascular diseases. The company relies on collaboration with other research institutes and biotech companies. The products of VIA Pharmaceuticals are currently still in clinical development but show promising results and could contribute to making the treatment of cardiovascular diseases more effective and with fewer side effects in the future. VIA Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding VIA Pharmaceuticals's Return on Assets (ROA)

VIA Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing VIA Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider VIA Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in VIA Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about VIA Pharmaceuticals stock

What is the Return on Assets (ROA) of VIA Pharmaceuticals this year?

The Return on Assets (ROA) of VIA Pharmaceuticals is 0 undefined this year.

What was the ROA of VIA Pharmaceuticals compared to the previous year?

The ROA of VIA Pharmaceuticals has increased by 0% compared to the previous year.

What consequences do high ROA have for investors of VIA Pharmaceuticals?

A high ROA is advantageous for investors of VIA Pharmaceuticals, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in VIA Pharmaceuticals?

A low ROA can be unfavorable for investors of VIA Pharmaceuticals as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of VIA Pharmaceuticals affect the company?

An increase in ROA of VIA Pharmaceuticals can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of VIA Pharmaceuticals impact the company?

A reduction in the ROA of VIA Pharmaceuticals can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of VIA Pharmaceuticals?

Some factors that can influence the ROA of VIA Pharmaceuticals include revenue, operating costs, asset structure, and industry average.

Why is the ROA of VIA Pharmaceuticals important for investors?

The ROA of VIA Pharmaceuticals is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can VIA Pharmaceuticals take to improve ROA?

To improve ROA, VIA Pharmaceuticals can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does VIA Pharmaceuticals pay?

Over the past 12 months, VIA Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, VIA Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of VIA Pharmaceuticals?

The current dividend yield of VIA Pharmaceuticals is .

When does VIA Pharmaceuticals pay dividends?

VIA Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of VIA Pharmaceuticals?

VIA Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of VIA Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is VIA Pharmaceuticals located?

VIA Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von VIA Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of VIA Pharmaceuticals from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.

When did VIA Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/5/2024.

What was the dividend of VIA Pharmaceuticals in the year 2023?

In the year 2023, VIA Pharmaceuticals distributed 0 USD as dividends.

In which currency does VIA Pharmaceuticals pay out the dividend?

The dividends of VIA Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von VIA Pharmaceuticals

Our stock analysis for VIA Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of VIA Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.